Clinical Trial Update: Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pembrolizumab in recurrent, platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers with CPS > 1.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Conditions: Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 2 | Status: UNKNOWN